Priest, R G, Gimbrett, R, Roberts, M et al. · Acta psychiatrica Scandinavica. Supplementum · 1995 · DOI
This review examines moclobemide and similar medications called RIMAs, which work by affecting brain chemicals involved in mood. The medication has proven effective for depression and is being tested in chronic fatigue syndrome (ME/CFS). Researchers note it may also help with anxiety, social phobia, and other conditions, with fewer side effects than older antidepressants.
This review is historically significant as it documents early clinical interest in moclobemide for ME/CFS treatment during the 1990s. Understanding which medications were explored and the rationale behind their use (targeting neurochemical dysfunction) informs current research into biological mechanisms and treatment strategies in ME/CFS.
This review does not provide definitive evidence that moclobemide is effective for ME/CFS, as the actual trial results are not presented—only that clinical trials were underway. The review's broad coverage of multiple conditions does not establish efficacy in any single disorder; it represents clinical hypothesis and preliminary findings rather than proven treatments. No data on ME/CFS outcomes, patient populations, or study design are provided.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →